Former Verily Leaders Build AI Platform to Get More from Proteomics Data
Tesorai’s AI platform reanalyzes massive proteomics repositories, letting researchers mine raw mass spectrometry data instead of condensed forms.
Biotechnology: gene and cell therapies, gene editing, mRNA, biologics and new drugs, clinical trials and FDA decisions, and the biotech companies and investors behind them, from BioPharma Dive, STAT, GEN and the news, with research from Nature Biotechnology and journals.
152 news articles and 115 research items in this section, back to 13 October 2026. Browse the news ↓ Research ↓
11 stories from 5 publishers in the last 24 hours, 76 from 15 this week.
Tesorai’s AI platform reanalyzes massive proteomics repositories, letting researchers mine raw mass spectrometry data instead of condensed forms.
Extracellular vesicles produced by certain types of pluripotent stem cells (PSC) were found to help reduce immune attacks on insulin-producing cells in the pancreas and delay the onset of diabetes in a mouse model.
It forces the medical community to treat these therapies with clinical gravity instead of casual enthusiasm.
The approval culminates a winding development journey for Infilbray, and provides Sanofi with a new source of income ahead of Dupixent’s looming patent expiration.
Most mentioned in Biotechnology headlines, last 3 days: STAT 9FDA 8Drug 8China 5Disease 4Cancer 4Mice 3biotech 3Isomorphic 3Genetic 3
Most active this week: GEN (Genetic Engineering & Biotechnology News) (22), BioPharma Dive (21), STAT Biotech (19), The Hill (2). Built automatically from headlines; the top items are the stories the most newsrooms covered in the last three days.
Alphabet's Isomorphic Labs closes a $5 billion raise, the biggest biotech cash infusion of the year, as AI-driven drug discovery draws capital even while late-stage results and regulatory decisions remain mixed.
The week was dominated by capital flows into AI-enabled drug discovery: Isomorphic Labs secured $5 billion led by Greenoaks and Sequoia with a 'significant' contribution from Alphabet, described as the two largest cash infusions in biotech this year, and Flagship committed £100 million to build 'AI-native platform companies' in the UK 156. Dealmaking by large pharma continued apace, with Lilly's $1.5 billion purchase of Calytrix marking its 15th announced acquisition of the year and J&J paying $2.2 billion for Ollin's vision-loss drug 2024. Regulators sent contrasting signals, approving Roche's breast cancer pill but refusing Summit's PD-1/VEGF drug ivonescimab over its failure to extend survival 417. Meanwhile, strong trial data from CG Oncology and Sellas contrasted with a STAT analysis noting that positive clinical results are not being uniformly rewarded by investors 8192123.
Written by Claude Fable 5.1 (Anthropic), based on 34 recent headlines and excerpts in this section, 2d ago. AI analysis can misread or miss things: the numbers link to the original reporting, which is the authority.
Journal articles, academic blogs, think-tank reports and papers, kept apart from the news below.
Nature Biotechnology, Published online: 19 November 2026; doi:10.1038/s41587-026-03362-3 RhoAgent designs functional RNA molecules by constraining secondary structure, base interactions and functional motifs.
Nature Biotechnology, Published online: 17 November 2026; doi:10.1038/s41587-026-03405-9 Author Correction: The global patent landscape of bispecific antibodies: technological innovations and therapeutic applications
Nature Biotechnology, Published online: 16 November 2026; doi:10.1038/s41587-026-03344-5 Adeno-associated virus vectors targeted to CD7 enable T and NK cell engineering in vivo.
Nature Biotechnology, Published online: 13 November 2026; doi:10.1038/s41587-026-03379-8 False discovery rate (FDR) control is central to omics research, yet the diverse procedures used rely on different assumptions. This Comment proposes a 2 × 2 matrix that helps sequencing-based and mass-spectrometry-based omics researchers choose the appropriate family of FDR procedures, or alternative methods that may be more rigorous, depending on data and study design.
Nature Biotechnology, Published online: 12 November 2026; doi:10.1038/s41587-026-03378-9 An analysis of Investigational New Drug (IND) submissions to the US Food and Drug Administration (FDA) from 1995 to 2025 reveals a rapid growth in adeno-associated virus (AAV) development over three decades and highlights common reasons for regulatory holds that should be considered for successful product development.
Discovering hit molecules requires not just high binding affinity, but also the identification of diverse binding modes, which are critical for experimental assays. Existing generative approaches have predominantly relied on optimizing a scalar docking score, obscuring the distinct contributions of key binding determinants. To this end, we introduce a paradigm shift by formulating target-based drug design as a multi-objective exploration task, where each objective explicitly…

Tesorai’s AI platform reanalyzes massive proteomics repositories, letting researchers mine raw mass spectrometry data instead of condensed forms. In an Alzheimer’s project, it found phosphorylated tau 217 in four datasets where the original authors did not report it.

Extracellular vesicles produced by certain types of pluripotent stem cells (PSC) were found to help reduce immune attacks on insulin-producing cells in the pancreas and delay the onset of diabetes in a mouse model.

It forces the medical community to treat these therapies with clinical gravity instead of casual enthusiasm.

The approval culminates a winding development journey for Infilbray, and provides Sanofi with a new source of income ahead of Dupixent’s looming patent expiration.

Lawmakers leading the congressional BIOTech Caucus say Washington needs to act in the sector — and fast:

Two telehealth giants rolled out peptide programs this week after HHS made it easier for compounding pharmacies to offer drugs like BPC-157.

A commission called on U.S. lawmakers to act quickly to prevent an “overdependence” on China that could leave American patients “vulnerable to supply chain weaponization.”
The product of a collaboration with Alnylam, Livsayis is now Regeneron’s first marketed RNAi drug and will compete against established medicines from AstraZeneca and Argenx.

Merck and Isomorphic Labs said they are entering into a research collaboration to discover small molecule candidates in oncology.

Did the biotech company Erasca find a more potent, better-tolerated pan-RAS cancer drug than Revolution Medicines?

China is intensifying efforts to control the entire drug supply chain, putting the U.S. at risk of being cut off from future lifesaving treatments, the National Security Commission on Emerging Biotechnology warns in a new analysis out Thursday. Why it matters: Western drug giants have invested huge sums in Chinese biotechs to boost their product pipelines. But sharing capital and expertise could give Beijing more control over critical pharmaceutical technologies. Concerns…

Researchers combined measurements from brain images and single cell transcriptome maps to build a resource, HypoAD, as an atlas of the human hypothalamus in aging and AD, which they have made available to the research community.

Researchers studying human induced pluripotent stem cell-derived microglia-like cells showed how genetic variants can impact cell behavior and used CRISPR gene editing to show how one gene’s effect depends on its cellular context.

Targeting FOLR1 with an approved antibody-drug conjugate restored anti-tumor immunity and enhanced anti-PD-1 effectiveness in colorectal cancer, overcoming immune evasion in mouse models.

Flagship expects to recruit and train an initial team of approximately 50 U.K.-based scientist-entrepreneurs and operators for the new Origination Lab, U.K., which will build on three years of experience partnering and conducting R&D across the kingdom.

STAT tackles the most important questions about the FDA's uncertain future.

Proponents of compounding argue it increases access, lowers prices and helps patients who may need individualized versions of a drug. But there are serious concerns, experts said at the HLTH conference.

Automating engineered TIL manufacturing in a way that maintains their tumor-fighting capabilities may move this emerging therapeutic class into a commercially reproducible, economically viable therapeutic option.

The complexity of extracellular vesicle products developed from umbilical cord blood can potentially be reduced through production processes and simplified quality control strategies, helping to boost this new product class.

ParkourSC acquired manufacturing-AI company Quartic to track a drug’s quality across its whole lifecycle. CEO Mahesh Veerina explains how linking factory and shipping data could flag at-risk batches before problems reach patients.

Growth-based sterility testing works for traditional biopharma but is too slow for the cell therapy sector. A new parallel testing pathway and rapid, molecular assay-based testing are a better option.

The sudden end of Heidi Overton’s candidacy likely ensures a Democrat-controlled Congress will choose the FDA’s next leader — but shouldn’t disrupt the agency, analysts say.

The potentially $2.6 billion collaboration puts Pfizer into a competitive race to treat autoimmune conditions by reprogramming cells inside the body.

The FDA published its complete response letter to Summit Therapeutics explaining why it rejected the biotech's closely watched lung cancer drug:

The FDA had several issues with ivonescimab, according to the letter. Elsewhere, Sellas shares rocketed on results for a leukemia vaccine and Biogen and Lilly struck up new R&D pacts.

A lag in foundational research and looming geopolitical risks will weigh on China’s bid to build a world-class biotechnology innovation ecosystem, even as the sector’s overseas momentum remains strong, according to JPMorgan. “In China, there is still some catching up to do in basic research, particularly in biological and pharmaceutical research,” said Yang Huang, head of China healthcare research at JPMorgan, during an interview on Wednesday. To meet the “ambitious goal”…

Hong Kong needs more “patient capital” and more talent capable of commercialising research and development to sustain the city’s biotechnology ecosystem, according to a senior executive at a local biotech start-up. Yicura BioMed, based in the Hong Kong Science Park, is heading towards an initial public offering (IPO) in the city as soon as practicable, CEO Xian Jin said in an interview. “Biotech start-up fundraising in Hong Kong is never an easy game to play,” Jin said…
Isomorphic Labs Ltd. today announced that it has closed a $5 billion investment led by Greenoaks and Sequoia Capital. The venture capital firms were joined by more than a half-dozen other backers. The group included Isomorphic parent Alphabet Inc., which made a “significant investment.” The search giant provided the capital through its GV and CapitalG startup

In mice, alcohol cut the efficacy of anti-PD-1 immunotherapy by roughly 50%, suppressing tumor-infiltrating and memory T cells while boosting TIGIT-carrying ones. Blocking TIGIT restored the response.

ImmunoBrain's approach contrasts with decades of conventional thinking among researchers, which held that Alzheimer’s was a disease of toxic proteins—an outgrowth of thinking that immune activity in the brain was in itself a sign of pathology.